Summary In breast cancer, several investigations have demonstrated that the tumour biological factors uPA urokinase-type plasminogen activator) and its inhibitor PAI-1 are statistically independent, strong prognostic factors for disease-free (DFS) and overall survival (OS). However, statistical analyses performed for varying follow-up periods suggested a time variation of prognostic strength. We therefore investigated the time-dependent prognostic power of uPA, PAI-1 and steroid hormone receptor status applying the time-varying coefficient model of Gray. uPA and PAI-1 were analysed by enzyme-linked immunosorbent assay in tumour tissue extracts from 314 breast cancer patients. Hormone receptors (oestrogen and progesterone) were determined by radioligand binding or by immunohistochemistry. Univariate and multivariate analyses (Cox proportional hazards model) of DFS and OS were performed for all patients, including 147 node-negative patients. Median follow-up of patients still alive at time of analysis (n = 232) was 58 months. Although initially of high prognostic impact, a continuous decrease over time in the prognostic power of hormone receptor status and uPA was observed. In contrast, the prognostic impact of PAI-1 increased over time and reached similar strength as the lymph node status. The time-dependent risk profile of prognostic factors may have important clinical implications in regard to follow-up and patients' individual risk situation. Evaluation of time dependency of prognostic factors may also give a more profound insight into the dynamics of breast cancer metastasis.
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Keywords: prognosis, breast cancer, steroid hormone receptor, urokinase-type plasminogen activator, PAI-1, urokinase, protease, time variation Breast cancer is a heterogeneous disease showing great variability of biological and clinical behaviour. The high prevalence of this disease in developed countries has stimulated vivid interest in the exploration and validation of those tumour biological parameters that may identify patients at risk. In this respect, determination of the tumour biological factors uPA (urokinase-type plasminogen activator) and its inhibitor PAI-I is an important issue to address, as there is substantial evidence that high concentrations of these factors in primary cancer tissue are conducive to tumour cell spread and metastasis in breast cancer patients (Duffy et al, 1988; Janicke et al, 1990; 1991; Foekens et al, 1992; Grondahl-Hansen et al, 1993; Duggan et al, 1995) .
uPA and PAI-I are strong and independent prognostic factors in both node-negative and node-positive patients; elevated antigen levels of uPA or PAI-I are correlated with short disease-free survival and early death (Duffy et al, 1990; Janicke et al, 1993; Foekens et al, 1992; Grondahl-Hansen et al, 1993; Duggan et al, 1995) . Statistical analyses performed at different times of follow-up, however, suggest that the prognostic strength varies with time (Janicke et al, 1990; 1991; Altman et al, 1994) . Here, we analyse the time-varying impact of uPA and PAI-I in addition to that of the traditional biological prognostic factor, steroid hormone receptor status, on breast cancer prognosis applying the time-varying coefficient model of Gray (1992) . In this model, the effect of variables on relative risk (e.g. in diseasefree survival) is assessed by employing an extension of the Cox proportional hazards model (Cox, 1972) : the coefficient P, which in the Cox model is assumed to be constant in time, is replaced by the time-varying function [B(t).
PATIENTS AND METHODS Patients
In a prospective observational study (1987-9 1), 314 patients with invasive breast cancer were enrolled (Table 1) . Fresh tumour tissue was dissected by the pathologist and representative samples were snap frozen for subsequent determination of uPA and PAI-1 antigen content. Laboratory and patient data were documented in a computerized database after completion of primary therapy. Follow-up data were obtained every 3 months. Primary treatment was by modified radical mastectomy or by breast-conserving surgery, including axillary lymph node dissection. Patients with distant metastases at the time of primary surgery (M1) were not included in the study. The median number of axillary lymph nodes removed was 18 (5-45) and the median tumour diameter 2.5 cm (0.5-15 cm). The decision as to whether chemotherapeutic or hormonal adjuvant therapy should be applied was made strictly without consideration of uPA and PAI-I antigen tissue levels and solely based on the general consensus at the time of treatment. Patients with axillary lymph node involvement received either uPA, PAI-i and steroid hormone receptor status in breast cancer prognosis 307 adjuvant chemotherapy (n = 66) and/or adjuvant hormone therapy with tamoxifen (post-menopausal patients, n = 99); 11 node-positive patients received no form of adjuvant treatment. In the nodenegative group, 125 patients did not receive any kind of adjuvant treatment; five patients were subjected to chemotherapy and 17 patients received tamoxifen (see Table 1 ). (Janicke et al, 1990; 1991; 
Statistical analysis
The prognostic impact of uPA and PAI-I (disease-free and overall survival) was first analysed by the Cox proportional hazards model (Cox, 1972) using the SPSS software package (SPSS, Chicago, IL, USA) and by the CART Classification and Regression Trees) technique (Breiman et al, 1984) . For this statistical analysis, continuous as well as discrete breast cancer-related covariates were included, all of which were considered as fixed (not time dependent). Determination of the optimum cut-off for uPA and PAI-I to discriminate low-risk and high-risk patients was performed using log-rank statistics and isotonic regression (Janicke et al, 1990; 1991; . The values with maximal log-rank test were taken for this discrimination. Group-oriented curves for disease-free and overall survival were calculated according to Kaplan and Meier (1958) . The relative risks associated with the various prognostic variables after discrimination into high-risk and low-risk groups were estimated by the Cox proportional hazards model. All tests were performed at a significance level of a = 0.05. The influence of adjuvant systemic therapy was tested by carrying out an additional Cox proportional hazard analysis including chemotherapy and hormone therapy as 'prognostic variables'. The Cox proportional hazards model is based on the assumption that the relative risk (RR) associated with a factor x compared with a factor value x = 0 is described by RR(x) = exp(,x), with the coefficient independent of time. Prognostic factors may, however, have a changing influence on disease-free or overall survival probability with time (Gray, 1992; Lipponen et al, 1992; Yoshimoto et al, 1993) . To reveal the time-varying effect of uPA, PAI-1, the steroid hormone receptor status and the axillary lymph node status on breast cancer prognosis, the extended Cox proportional hazards model of Gray was applied. In this timevarying coefficient model, the time constancy assumption on P is relaxed and it is allowed to be a function of time, P(t). The relative risk associated with a factor x is thus modelled by RR(t,x) = exp (P(t)x). If x is a binary variable, this expression reduces to RR( t) = exp (5(t)). The function 5(t) is obtained by estimating , at numerous intervals in time and then smoothing over these pointwise estimates using spline functions. These analyses were performed with the S-Plus statistical software package (Statistical Sciences, 1993) .
RESULTS
Breast cancer patients with high levels of either uPA (> 3 ng mg' protein) or PAI-I (> 14 ng mg' protein) in their primary tumours (Janicke et al, 1991) Gray (1992) . (Figure TB) . Evidently, after this time, uPA has lost its independent prognostic power. The time-varying impact of PAT-i is opposite to that of uPA and steroid hormone receptor status ( Figure IC) . The prognostic impact of PAI-1 increases with observation time, reaching a peak level at about 33 months. Evidently, for uPA and steroid hormone receptor status, high relative risks indicate early disease recurrence whereas a high PAI-I risk profile is associated with later relapse. A similar trend as displayed in Figure 1 for node-negative patients is demonstrated in Figure 2 for the entire group of breast cancer patients including those with node-negative and node-positive disease. Initially, at 6 months, the axillary lymph node status turns out to be of highest prognostic impact. This effect levels off slightly over time. Similar to node-negative breast cancer, both steroid hormone receptor status and uPA indicate early disease recurrence, in contrast to the time-varying impact of PAI-1, which increases with the observation time, reaching similar strength in predicting disease-free survival as the axillary lymph node status.
DISCUSSION
Time dependency of the impact of axillary lymph node and steroid hormone receptor status on prognosis in breast cancer patients was first shown by Gray in 1992. We have applied his modified Cox model to study the time-varying impact on prognosis of the new tumour biological factors uPA (urokinase-type plasminogen activator) and PAI-I (inhibitor type 1 to uPA) and also included the traditional prognostic factors, axillary lymph node status and steroid hormone receptor status, in this analysis. The power of uPA to predict recurrences was strong in the first 3 years, especially in node-negative patients, but declined substantially thereafter. This time-related pattern of uPA was similar to that already described for steroid hormone receptor status. In contrast, the prognostic impact of PAI-1 increases over time and becomes even stronger in predicting disease-free survival than axillary lymph node status. On the other hand, the relative risk for recurrence, as indicated by axillary lymph node status, after an initial decline does not vary essentially throughout the observation period. In node-negative breast cancer patients, PAI-1 even prevails as the only independent prognostic factor in our analysis. Confounding effects of adjuvant therapy might have influenced these results. Thus, adjuvant therapy was included as a prognostic variable in the statistical analysis. However, the application of adjuvant therapy was not an independent risk factor. An interaction between prognostic factors and adjuvant therapy affecting the outcome of the statistical analysis could therefore be excluded. Invasion and metastasis of solid tumours require the degradation of the extracellular matrix and of the basement membrane at the site of the primary tumour and at distant loci. Hence, proteolysis and remodelling of the matrix at the metastatic site are essential. Proteases such as uPA, matrix metalloproteases, cathepsins, plasmin and thrombin and their inhibitors are involved in these processes Brunner et al, 1994) . Efficient tumour cell invasiveness, focal proteolysis and metastasis with secondary tumour growth are based on a critical balance between proteases, their cell-surface receptors and inhibitors (Liu et al, 1995) . Tumour biological studies have attributed a key role to uPA, its cell-surface-bound receptor (uPA-R) and PAI-I in these events. The overexpression of uPA-R in breast cancer cells results in increased tumour invasion and metastasis in an experimental model (Xing and Rabbani, 1996) . uPA-R is a major binding protein to the vitronectin-rich extracellular matrix (Kanse et al, 1996) . It (Felsenfeld et al, 1996; Wei et al, 1996) . Indeed, in addition to breast cancer, a strong impact on prognosis of uPA content in tumour tissue has been observed in many other malignancies, e.g. cancer of the ovary (Kuhn et al, 1994) , stomach (Nekarda et al, 1994; Heiss et al, 1995) , colon , lung (Pedersen et al, 1994) , kidney (Hofmann et al, 1996) , bladder (Hasui et al, 1989 ) and cervix uteri (Kobayashi et al, 1994) . It is rather difficult to understand that the tumour tissue content of the uPA inhibitor PAI-I on an even larger scale indicates a poor prognosis for the cancer patient. Suggestions to explain these findings are that PAI-1 is a prerequisite for the matrix formation at the metastatic site by protecting the tumour against tumour-associated proteases . Recent observations indicate an even broader role for PAI-1 in tumour biology. It may be involved in the modulation of the uPA-R binding to vitronectin (Kanse et al, 1996) and is thought to inhibit cell attachment to the extracellular matrix (Stefansson and Lawrence, 1996) , thus enabling tumour cells to migrate in a stepwise fashion, alternately being attached to the extracellular matrix or detached from it. These findings underline the strong effect of PAI-1 on the malignant phenotype of the tumour cell and are in line with the observation that coexpression of uPA, its receptor and PAI-I is necessary for focalized and optimal invasiveness (Estreicher et al, 1990; Liu et al, 1995) , as well as for angiogenic activity (Barbareschi et al, 1995) .
Shedding and dissemination of tumour cells is a very common phenomenon in solid tumours, especially in breast cancer. The presence of tumour cells distant from the primary tumour, however, is not a definite sign for later occurrence of distant metastases. So-called dormant micrometastases may be present for years and may even disappear spontaneously or develop angiogenic activity and switch to the expanding, invasive phenotype by different, unknown stimuli (Holmgren et al, 1995) . These stimuli may also involve, among other things, the plasminogen-activating system mediated by the tumour cell surface-located receptor for uPA (uPA-R). Indeed, Heiss et al (1995) in a recent study demonstrated that the presence of uPA-R on disseminated tumour cells detected in bone marrow aspirates of gastric cancer patients is a strong indicator for the development of later clinical metastases. Thus, the occurrence of clinically detectable metastases seems to depend on the biological properties of the disseminated tumour cell. One might speculate that tumour cells exhibiting a high capacity to synthesize uPA are primarily of the invasive phenotype or will switch early during the course of disease to invasiveness, whereas those producing high levels of PAI-I will become invasive at a later time. Studying the time variation of the risk associated with these and other factors may give important insights into their role in tumour cell dissemination and metastasis.
Our findings may still be well short of changing clinical practice at the moment. However, both the absence of steroid hormone receptors and high uPA tumour levels in breast cancer patients can be said to be indicators of early disease recurrence. In patients with steroid hormone receptor-negative tumours or tumours with high uPA content, who remain disease free during the first 2 years of follow-up, late recurrence tends to be rare. On the other hand, patients with high PAI-i tumour levels have the highest relative risk of recurrence during the second and third years. In conclusion, the knowledge of the time-dependent risk profile of prognostic factors in breast cancer might have important clinical implications regarding follow-up and the assessment of the patient's individual risk situation.
